Imprimis Pharmaceuticals (IMMY) & The Competition Financial Survey

Imprimis Pharmaceuticals (NASDAQ: IMMY) is one of 290 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Imprimis Pharmaceuticals to similar companies based on the strength of its analyst recommendations, profitability, risk, earnings, valuation, dividends and institutional ownership.


This table compares Imprimis Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Imprimis Pharmaceuticals -60.71% -264.98% -57.30%
Imprimis Pharmaceuticals Competitors -5,461.98% -161.08% -36.47%

Insider and Institutional Ownership

12.6% of Imprimis Pharmaceuticals shares are owned by institutional investors. Comparatively, 49.3% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 12.6% of Imprimis Pharmaceuticals shares are owned by insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Imprimis Pharmaceuticals and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Imprimis Pharmaceuticals $19.94 million -$19.08 million -1.84
Imprimis Pharmaceuticals Competitors $290.27 million $35.99 million 62.80

Imprimis Pharmaceuticals’ rivals have higher revenue and earnings than Imprimis Pharmaceuticals. Imprimis Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Imprimis Pharmaceuticals and its rivals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Imprimis Pharmaceuticals 0 0 1 0 3.00
Imprimis Pharmaceuticals Competitors 1175 3520 12059 248 2.67

Imprimis Pharmaceuticals presently has a consensus target price of $5.00, indicating a potential upside of 195.86%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 33.47%. Given Imprimis Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Imprimis Pharmaceuticals is more favorable than its rivals.

Volatility and Risk

Imprimis Pharmaceuticals has a beta of -0.51, indicating that its stock price is 151% less volatile than the S&P 500. Comparatively, Imprimis Pharmaceuticals’ rivals have a beta of 2.60, indicating that their average stock price is 160% more volatile than the S&P 500.


Imprimis Pharmaceuticals rivals beat Imprimis Pharmaceuticals on 9 of the 13 factors compared.

About Imprimis Pharmaceuticals

Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.

Receive News & Ratings for Imprimis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply